Los Angeles Capital Management LLC Prothena Corp Public LTD CO Transaction History

Los Angeles Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	SELL	$52.05 - $65.0 $27,586 - $34,450	-530 Reduced 8.68%	5,576 $335,000
Q3 2022 Nov 02, 2022	BUY	$25.16 - $60.63 $153,626 - $370,206	6,106 New	6,106 $370,000
Q4 2021 Feb 03, 2022	SELL	$42.11 - $73.26 $743,030 - $1.29 Million	-17,645 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$48.2 - $78.89 $812,170 - $1.33 Million	-16,850 Reduced 48.85%	17,645 $1.26 Million
Q2 2021 Aug 05, 2021	SELL	$21.63 - $57.65 $101,228 - $269,802	-4,680 Reduced 11.95%	34,495 $1.77 Million
Q1 2021 May 05, 2021	SELL	$11.0 - $28.24 $4,400 - $11,296	-400 Reduced 1.01%	39,175 $984,000
Q4 2020 Feb 04, 2021	SELL	$10.12 - $13.94 $20,948 - $28,855	-2,070 Reduced 4.97%	39,575 $475,000
Q3 2020 Nov 02, 2020	BUY	$9.93 - $13.47 $8,539 - $11,584	860 Added 2.11%	41,645 $416,000
Q2 2020 Aug 05, 2020	BUY	$9.56 - $12.51 $201,572 - $263,773	21,085 Added 107.03%	40,785 $426,000
Q1 2020 May 04, 2020	BUY	$7.54 - $15.77 $148,538 - $310,669	19,700 New	19,700 $211,000

190

42.9M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $661M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.